Cortecs, a young UK-based company with Australian origins, has a growi
ng portfolio of patent applications offering worldwide protection for
potential products. Fields of particular interest include diagnosis of
Helicobacter pylori and other infections, vaccine technology, solubil
isation and drug delivery, and enzymes in intracellular signal transdu
ction. From information concerning pending patent applications, it see
ms that therapeutic targeting is to be an important feature of Cortecs
' future development work.